Setanaxib
- Generic Name
- Setanaxib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O2
- CAS Number
- 1218942-37-0
- Unique Ingredient Identifier
- 45II35329V
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Calliditas Therapeutics AB
- Target Recruit Count
- 18
- Registration Number
- NCT06274489
- Locations
- 🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom
🇦🇹Medizinische Universitaet Wien, Vienna, Wien, Austria
🇫🇷HCL Hopital Edouard Herriot, Lyon, France
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 55
- Registration Number
- NCT05323656
- Locations
- 🇫🇷
Ramsay Health Clinic Belharra, Bayonne, France
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇬🇧The Royal Marsden Hospital - London, London, England, United Kingdom
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Calliditas Therapeutics Suisse SA
- Target Recruit Count
- 76
- Registration Number
- NCT05014672
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇦🇹Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, Oberösterreich, Austria
🇵🇱ID Clinic, Myslowice, Poland
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Calliditas Therapeutics AB
- Target Recruit Count
- 64
- Registration Number
- NCT04327089
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath